142 related articles for article (PubMed ID: 10752989)
1. Leukemia and myelodysplasia effect of multiple cytotoxic therapy in essential thrombocythemia.
Randi ML; Fabris F; Girolami A
Leuk Lymphoma; 2000 Apr; 37(3-4):379-85. PubMed ID: 10752989
[TBL] [Abstract][Full Text] [Related]
2. Leukemia and myelodysplasia in patients with essential thrombocythemia treated with cytotoxic agents.
Randi ML; Fabris F; Girolami A
Haematologica; 1999 Nov; 84(11):1049-50. PubMed ID: 10553169
[No Abstract] [Full Text] [Related]
3. Leukemogenic risk of hydroxyurea therapy in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis.
Nand S; Stock W; Godwin J; Fisher SG
Am J Hematol; 1996 May; 52(1):42-6. PubMed ID: 8638610
[TBL] [Abstract][Full Text] [Related]
4. Acute myeloid leukemia and myelodysplastic syndromes following essential thrombocythemia treated with hydroxyurea: high proportion of cases with 17p deletion.
Sterkers Y; Preudhomme C; Laï JL; Demory JL; Caulier MT; Wattel E; Bordessoule D; Bauters F; Fenaux P
Blood; 1998 Jan; 91(2):616-22. PubMed ID: 9427717
[TBL] [Abstract][Full Text] [Related]
5. Second malignancies in patients with essential thrombocythaemia treated with busulphan and hydroxyurea: long-term follow-up of a randomized clinical trial.
Finazzi G; Ruggeri M; Rodeghiero F; Barbui T
Br J Haematol; 2000 Sep; 110(3):577-83. PubMed ID: 10997967
[TBL] [Abstract][Full Text] [Related]
6. Long-term incidence of hematological evolution in three French prospective studies of hydroxyurea and pipobroman in polycythemia vera and essential thrombocythemia.
Kiladjian JJ; Rain JD; Bernard JF; Briere J; Chomienne C; Fenaux P
Semin Thromb Hemost; 2006 Jun; 32(4 Pt 2):417-21. PubMed ID: 16810617
[TBL] [Abstract][Full Text] [Related]
7. Acute leukemia and myelodysplasia in patients with a Philadelphia chromosome negative chronic myeloproliferative disorder treated with hydroxyurea alone or with hydroxyurea after busulphan.
Nielsen I; Hasselbalch HC
Am J Hematol; 2003 Sep; 74(1):26-31. PubMed ID: 12949887
[TBL] [Abstract][Full Text] [Related]
8. Risk of leukaemia, carcinoma, and myelofibrosis in 32P- or chemotherapy-treated patients with polycythaemia vera: a prospective analysis of 682 cases. The "French Cooperative Group for the Study of Polycythaemias".
Najean Y; Rain JD; Dresch C; Goguel A; Lejeune F; Echard M; Grange MJ
Leuk Lymphoma; 1996 Sep; 22 Suppl 1():111-9. PubMed ID: 8951781
[TBL] [Abstract][Full Text] [Related]
9. Acute myeloid leukemia (AML) having evolved from essential thrombocythemia (ET): distinctive chromosome abnormalities in patients treated with pipobroman or hydroxyurea.
Bernasconi P; Boni M; Cavigliano PM; Calatroni S; Brusamolino E; Passamonti F; Volpe G; Pistorio A; Giardini I; Rocca B; Caresana M; Lazzarino M; Bernasconi C
Leukemia; 2002 Oct; 16(10):2078-83. PubMed ID: 12357360
[TBL] [Abstract][Full Text] [Related]
10. Second malignancies in essential thrombocythemia (ET): a retrospective analysis of 331 patients with long-term follow-up from a single institution.
Radaelli F; Onida F; Rossi FG; Zilioli VR; Colombi M; Usardi P; Calori R; Zanella A
Hematology; 2008 Aug; 13(4):195-202. PubMed ID: 18796244
[TBL] [Abstract][Full Text] [Related]
11. Treatment strategies in essential thrombocythemia. A critical appraisal of various experiences in different centers.
Barbui T; Finazzi G; Dupuy E; Kiladjian JJ; Brière J
Leuk Lymphoma; 1996 Sep; 22 Suppl 1():149-60. PubMed ID: 8951786
[TBL] [Abstract][Full Text] [Related]
12. Transition of essential thrombocythemia to megakaryoblastic leukemia after long-term therapy with sequential busulfan, pipobroman and hydroxyurea.
Sironi M; Bertola G; Lodato A; Spinelli M; Sciariada L
Acta Haematol; 2003; 109(3):161-2. PubMed ID: 12714827
[No Abstract] [Full Text] [Related]
13. Treatment of polycythaemia vera and essential thrombocythaemia.
Tefferi A; Silverstein MN
Baillieres Clin Haematol; 1998 Dec; 11(4):769-85. PubMed ID: 10640216
[TBL] [Abstract][Full Text] [Related]
14. Myelodysplastic transformation in a case of essential thrombocythemia treated with pipobroman.
Messora C; Bensi L; Vanzanelli P; Temperani P; Carotenuto M; Sacchi S
Haematologica; 1996; 81(1):51-3. PubMed ID: 8900853
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of hydroxyurea in patients with essential thrombocythemia.
Finazzi G; Barbui T
Pathol Biol (Paris); 2001 Mar; 49(2):167-9. PubMed ID: 11317964
[TBL] [Abstract][Full Text] [Related]
16. Is hydroxyurea leukemogenic in essential thrombocythemia?
Tefferi A
Blood; 1998 Aug; 92(4):1459-60; author reply 1460-1. PubMed ID: 9694740
[No Abstract] [Full Text] [Related]
17. Myelodysplastic syndrome and secondary acute leukemia after treatment of essential thrombocythemia with hydroxyurea.
van den Anker-Lugtenburg PJ; Sizoo W
Am J Hematol; 1990 Feb; 33(2):152. PubMed ID: 2301374
[No Abstract] [Full Text] [Related]
18. [Treatment of essential thrombocythemia--personal experience].
Bieniaszewska M; Balon J; Brozek I; Limon J; Hellmann A
Pol Arch Med Wewn; 2000; 103(3-4):179-85. PubMed ID: 11236245
[TBL] [Abstract][Full Text] [Related]
19. Plasma cell leukemia occurring in a patient with thrombocythemia treated with hydroxyurea and busulphan.
Candoni A; Tiribelli M; Fanin R
Leuk Lymphoma; 2004 Apr; 45(4):821-4. PubMed ID: 15160964
[TBL] [Abstract][Full Text] [Related]
20. Acute myeloid leukemia evolving from essential thrombocythemia in two patients treated with hydroxyurea.
Furgerson JL; Vukelja SJ; Baker WJ; O'Rourke TJ
Am J Hematol; 1996 Feb; 51(2):137-40. PubMed ID: 8579054
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
